iShares Biotechnology ETF is an exchange-traded fund that seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. Launched in 2001 and managed by BlackRock, it provides investors with targeted exposure to companies engaged in the research, development, and commercialization of biotechnological products and services. The fund follows a modified market-cap-weighted approach via the NYSE Biotechnology Index, holding a diversified portfolio of over 250 biotechnology stocks. Key holdings include leading firms like Gilead Sciences, Vertex Pharmaceuticals, and Amgen, with primary allocations to biotechnology at around 88%, alongside smaller exposures to life sciences tools, pharmaceuticals, and health care services. This ETF plays a vital role in the financial markets by offering a convenient, liquid vehicle for accessing the innovative biotechnology industry, which drives advancements in therapeutics, genomics, and medical treatments. Distributed quarterly, it caters to those seeking sector-specific equity participation within the broader health care landscape.